Liquid Biopsy in Solid Tumor: An Ultimate Source for Molecular Landscaping, Biomarker Discovery and Clinical Management

Deep Kumari Yadav; Shayma Shaikh; Rakesh Rawal

doi:10.37591/rrjooh.v8i3.1725

Abstract

Presently, work in the liquid biopsy field showed a great prospect utility in the diagnosis and stratification of cancer patients and furthermore personify an adaptive method for monitoring treatment response when compared to the tissue biopsy approach. Analysis of cell free DNA (cfDNA), circulating tumor cells (CTCs) and exosomes, all conjointly referred to as “liquid biopsies,” are not only a modality to monitor treatment efficacy, disease progression, and emerging therapy resistance mechanisms, but they also assess tumor heterogeneity and evolution in real-time. This review concerned the different isolation, detection approaches, their role in cancer management and future outlook on the use of liquid biopsy in biomarker discovery. These biomarkers not only have prognostic values but also can help to lodge treatment decisions by monitoring tumor burden, detecting minimal residual disease or recurrent disease, as well as monitoring evolution of genetic alterations throughout the treatment course. Keywords: cancer management, cell-free DNA (cfDNA), circulating tumor cell (CTC), exosomes, liquid biopsy Cite this ArticleDeep Kumari Yadav, Shayma Shaikh, Rakesh Rawal. Liquid biopsy in solid tumor: An ultimate source for molecular landscaping, biomarker discovery and clinical management. Research & Reviews: Journal of Oncology and Hematology. 2019; 8(3): 25–36p.